Results overview: Found 1 records in 0.02 seconds.
Articles, 1 records found
Articles 1 records found  
1.
8 p, 354.8 KB A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma / Hájek, R (Faculty of Medicine. University of Ostrava) ; Pour, L. (University Hospital Brno (República Txeca)) ; Ozcan, M. (Ankara University School of Medicine) ; Martin Sánchez, J. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García Sanz, R. (Hospital Universitario de Salamanca) ; Anagnostopoulos, Achilles (George Papanicolaou General Hospital (Tessalònia, Grècia)) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Cascavilla, N. (Istituto di Ricovero e Cura A Carattere Scientifico (IRCCS)) ; Terjung, A. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Lee, Y. (Pharmacyclics LLC. an AbbVie Company) ; Briso, E. M. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Dobkowska, E. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Hauns, B. (Pharmacyclics Switzerland GmbH. an AbbVie Company) ; Špička, I. (Charles University. Faculty of Medicine in Hradec Králové) ; Universitat Autònoma de Barcelona
Objective: We evaluated ibrutinib, a once-daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1-3 prior therapies. [...]
2020 - 10.1111/ejh.13377
European Journal of Haematology, Vol. 104 Núm. 5 (january 2020) , p. 435-442  

See also: similar author names
1 Briso, E. M.
Interested in being notified about new results for this query?
Set up a personal email alert or subscribe to the RSS feed.